Corrigendum to “Change in 1-year hospitalization of overall and older patients with major depressive disorder after second-generation antipsychotics augmentation treatment” [J. Affect. Disord. 230(1) (2018) 118–124]

2018 ◽  
Vol 234 ◽  
pp. 162-163
Author(s):  
Chun-Yuan Lin ◽  
Te-Jen Lai ◽  
Yu-Hsin Wu ◽  
Ping-Kun Chen ◽  
Yuan-Fu Lin ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Older Patients ◽  
Second Generation ◽  
Major Depressive ◽  
Second Generation Antipsychotics

scholarly journals Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment

2020 ◽  
Vol 23 (7) ◽  
pp. 440-445 ◽  
Author(s):  
Markus Dold ◽  
Lucie Bartova ◽  
Siegfried Kasper
Keyword(s):  
Major Depressive Disorder ◽  
Confidence Interval ◽  
Depressive Disorder ◽  
Nasal Spray ◽  
Second Generation ◽  
Mean Difference ◽  
Inadequate Response ◽  
Major Depressive ◽  
Second Generation Antipsychotics ◽  
Second Generation Antipsychotic

Abstract In this meta-analysis, we aimed to estimate and compare the efficacy of add-on treatment of antidepressants with esketamine nasal spray and second-generation antipsychotics in patients with nonpsychotic major depressive disorder and inadequate response to antidepressants. Searching for acute-phase, double-blind, placebo-controlled, randomized trials, we found 22 second-generation antipsychotic (n = 8363) and 3 intranasal esketamine (n = 641) studies. Mean change in the Montgomery Åsberg Depression Rating Scale total score served as outcome. We determined a higher mean difference (vs placebo) for the pooled esketamine nasal spray trials (mean difference = 4.09, 95% confidence interval: 2.01 to 6.17) than for the pooled second-generation antipsychotic augmentation trials (mean difference  = 2.05, 95% confidence interval: 1.51 to 2.59). Thus, the effect size for intranasal esketamine was nearly twice as high as those for the second-generation antipsychotics. This indicates high efficacy of add-on esketamine nasal spray in treatment-resistant major depressive disorder compared with other well-established, evidence-based pharmacological options such as augmentation with second-generation antipsychotics.

Second-generation antipsychotics in the treatment of major depressive disorder: current evidence

2013 ◽  
Vol 13 (7) ◽  
pp. 851-870 ◽  
Author(s):  
Changsu Han ◽  
Sheng-Min Wang ◽  
Masaki Kato ◽  
Soo-Jung Lee ◽  
Ashwin A Patkar ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Second Generation ◽  
Current Evidence ◽  
Major Depressive ◽  
Second Generation Antipsychotics

Use of second generation antipsychotics for treatment-resistant major depressive disorder

2014 ◽  
Vol 4 (5) ◽  
pp. 246-256
Author(s):  
Rebecca Waite
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Symptoms ◽  
Adverse Effects ◽  
Depressive Disorder ◽  
Second Generation ◽  
Antidepressant Therapy ◽  
Treatment Resistant ◽  
Major Depressive ◽  
Quetiapine Xr ◽  
Second Generation Antipsychotics

Many of the second generation antipsychotics (SGAs) have been studied as adjunctive agents in the management of treatment-resistant major depressive disorder. Two have also been examined for use as monotherapy for depression. Currently, aripiprazole, olanzapine (in combination with fluoxetine), and quetiapine XR are approved by the FDA for use as adjunctive agents in the treatment of major depressive disorder, and no SGAs are FDA-approved as monotherapy for the disorder. This article reviews the available evidence regarding the use of SGAs in patients with treatment-resistant major depressive disorder and the subsequent role for these agents based on this evidence. There is evidence that aripiprazole, quetiapine, olanzapine, and risperidone can be effective in improving depressive symptoms when added to antidepressant therapy, but the benefits have to be weighed against their risk of producing serious adverse effects.

Sign in / Sign up

Export Citation Format

Share Document